Regional immunotherapy in resectable squamous cell lung carcinoma. Analysis of a randomized study.
Patients with resectable squamous cell carcinoma were randomly allocated after surgery to receive either no further treatment (57 patients) or a single intrapleural injection of BCG (61 patients). No significant improvement in survival was observed in patients treated with BCG, even when their disease was staged as N0. There was a slight trend for the recurrence rate to be lower in patients classed as N0, but this was not significant.
D001500:BCG Vaccine / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000601:surgery / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine